



GOVERNMENT OF PAKISTAN
(CABINET DIVISION)
INTELLECTUAL PROPERTY ORGANIZATION
THE PATENT OFFICE
KARACHI



To,

Dated: 06-05-2009

Mr. Munir Ahmed,
Director (Admn.),
IPO-Pakistan,
Islamabad.

**Subject: WEEKLY NOTIFICATION OF PATENT OFFICE FOR THE
WEEKENDING 24-04-2009 TO BE PUBLISHED 07-05-2009 IN THE
GAZETTE OF PAKISTAN PART-V.**

Sir,

Reference to IPO letter dated 12-5-2008 forwarding therewith copy of letter No 18/IPO/2008/ RA-IV dated 23-4-2008 from Cabinet Division on the above subject.

A manuscript copies of the weekly notification regarding application filed, application accepted and sealing fee due is enclosed herewith for onward transmission to the Cabinet Division for Publication in the next issue of the Gazette of Pakistan (Part –V)

(Mrs. Yasmeen Abbasi)
Controller of Patents
Ph: 9215488

ENCL:

NEW APPLICATIONS FOR THE PATENTS


The dates shown in the crescent brackets are the dates claimed under section 86 of the Patents Ordinance 2000

321/2009	<u>20-4-2009</u> AstraZeneca AB, Sweden (Priority 22-04-2008 USA)	“Substituted pyrimidin-5-carboxamides 281”
322/2009	Partex services Portugal-Servicos Para a Industria Petrolifera S.A., Portugal Antonio Jose Silva Valente Portugal (Priority 21-04-2008 Portugal)	“Pressure reduction plant for a gas or gas mixture”
323/2009	Tetra Laval Holdings & Finance S.A., Puly (Priority 21-4-2008 PCT/Sweden)	Inside creasing”
324/2009	Sanofi-Aventis, France (Priority 21-04-2008 France)	“1,3-dihydro-2h-pyrrolo[3,2-b]pyridine-2-one derivatives, their preparation and their therapeutic applications”
325/2009	Novartis AG, Switzerland (Priority 21-04-2008 India)	“Heterocyclic compounds as mek inhibitors”
326/2009	<u>21-04-2009</u> Schering Corporation, USA (Priority 28-04-2008 USA)	“High density compositions containing posaconazole and formulations comprising the same”
327/2009	Schering Corporation, USA (Priority 22-04-2008 USA)	“Thiophenyl-substituted 2-imino-3-methyl pyrrolo pyrimidinonecompounds as back-1 inhibitors, compositions, and their use”
328/2009	Schering Corpioration, USA (Priority 22-04-2008 USA)	“Thiophenyl-substituted 2-imino-3-methyl pyrrolo pyrimidinonecompounds as bace-1 inhibitors, compositions, and their use”
329/2009	Institute for One World Health, USA (Priority 21-04-2008 USA)	“Compounds compositions and methods comprising oxadiazole derivatives”
330/2009	BP Exploration Operating	“Slug mitigation”

	Company Limited, England (Priority 02-05-2008 Europe)	
331/2009	Institute for One World Health, USA (Priority 21-04-2008 USA)	“Compounds compositions and methods comprising pyridazine derivatives”
332/2009	Institute for One World Health, USA (Priority 21-04-2008 USA)	“Compounds compositions and methods comprising isoxazole derivatives”
333/2009	Institute for One World Health, USA (Priority 21-04-2008 USA)	“Compounds compositions and methods comprising thiazole derivatives”
334/2009	Institute for One World Health, USA (Priority 21-04-2008 USA)	“Compounds compositions and methods comprising triazine derivatives”
335/2009	Institute for One World Health, USA (Priority 21-04-2008 USA)	“Compounds compositions and methods comprising oxadiazole derivatives”
336/2009	Institute for One World Health, USA (Priority 21-04-2008 USA)	“High-throughput cell-based CFTR assay”
337/2009	Institute for One World Health, USA (Priority 21-04-2008 USA)	“Compounds compositions and methods comprising triazole derivatives”
338/2009	Otonomy, Inc., USA The Reagents of the University of California, USA (Priority 21-04-2008 USA)	“Auris-interna formulations for treating otic diseases and conditions”
	<u>22-04-2009</u>	
339/2009	Saudi Basic Industries Corporation, Saudi Arabia (Priority 24-04-2008 Europe)	“Flexible intermediate bulk container”
340/2009	Saudi Basic Industries Corporation, Saudi Arabia (Priority 24-04-2008 Europe)	“Process for making opaque polyester film”
341/2009	Spindelfabrik Suessen GmbH,	“A condensing unit for a drafting unit of a

	Germany (Priority 24-04-2008 Germany)	textile machine”
342/2009	Targacept, Inc, USA (Priority 05-03-2003 USA) Divisional	“Substituted pyridine compound”
343/2009	Targacept, Inc, USA (Priority 05-03-2003 USA) Divisional	“Substituted vinylazacycloalkane compound”
344/2009	Spindelfabrik Suessen GmbH, Germany (Priority 24-04-2008 Germany)	“A condensing unit and a top roller aggregate for a drafting unit of a textile machine”
345/2009	Spindelfabrik Suessen GmbH, Germany (Priority 24-04-2008 Germany)	“A condensing unit for a drafting unit of a textile machine”
346/2009	Takeda Pharmaceutical Company Limited, Japan (Priority 23-04-2008 Japan)	“Iminopyridine derivatives and use thereof”
347/2009	<u>24-04-2009</u> Next Proteins, Inc., USA (Priority 25-04-2008 USA)	“Protein beverage and method of making the same”
348/2009	First Green Park Pty Ltd., Australia (Priority 24-04-2008 Australia)	“Solar Stills”

and




366/2004 Glaxo Group
Limited.,
United Kingdom

“Quinoline compound”

CO7D 215/08

140078

There is provided according to the invention novel compound of formula (i) wherein R¹.R².R¹⁹. R²⁰. and R³⁴ as described in the specification formulation containing them and their use in therapy for the treatment of inflammatory diseases.



(I)


407/2004 F. Hoffmann-La
Roche AG,
Switzerland

“Imidazole compound”

CO7D 401/06

140079

The present invention relates to imidazole compound which is : mGluRS receptor antagonists and which are represented by the general formula I,



which may be used for the treatment or prevention of mGluR5 receptor mediated disorders, such as acute and/or chronic neurological disorders.

wherein

R¹ signifies halogen or cyano;

R² signifies lower alkyl;

R³ signifies aryl or heteroaryl, which are optionally substituted by one, two or three substituents, selected from the group consisting of halogen, lower alkyl, cycloalkyl, lower alkyl-halogen, cyano, lower alkoxy, NR'R'' or by 1-morpholinyl, or by 1-pyrrolidinyl, optionally substituted by (CH₂)_{0,1}OR, or by piperidinyl, optionally substituted by (CH₂)_{0,1}OR, or by 1,1-dioxo-thiomorpholinyl or by piperazinyl, optionally substituted by lower alkyl or (CH₂)_{0,1}-cycloalkyl;

R is hydrogen, lower alkyl or (CH₂)_{0,1}-cycloalkyl;

R',R'' are independently from each other hydrogen, lower alkyl, (CH₂)_{0,1}-cycloalkyl or (CH₂)_nOR;

n is 1 or 2;

R⁴ is hydrogen, C(O)H, CH₂R⁵ wherein R⁵ is hydrogen, OH, C₁-C₆-alkyl, C₃-C₁₂-cycloalkyl.

1199/2005 Honda Motor Co.,
Ltd.,
Japan

“A dog clutch for motorcycle”

F16D 11/10

140080

To enable to engage a dog clutch always by a single shifting operation, smoothly and with 3 lowered torque shock. [Solution] In a dog clutch comprising a first dog clutch member 32 coupled with a rotation transmitting member 11b rotatably mounted on a power transmission shaft 3 with a relative rotation clearance Θ , a second dog clutch

member 15b slidably mounted on the power transmission shaft 3 to be engageable/disengageable with/from the first dog clutch member 32, and a damper spring which is interposed between the rotation transmitting member 11b and the first dog clutch member 32, gear teeth-like first dog teeth 41 and second dog teeth 42, which are engaged/disengaged with/from each other by an axial displacement of the second dog clutch member 15b, are formed in the first dog clutch member 32 and the second dog clutch member 15b, respectively, and a chamfer 41a, 42a is made in each of end portions of the respective first dog teeth 41 and each of end portions of the respective second dog teeth 42, which are opposed to each other, so as to guide the second dog teeth 42 to a position to engage with the first dog teeth 41.


1111/2006 F. Hoffmann-La
Roche AG,
Switzerland

“A pharmaceutical acceptable salt of imidazole compound”

CO7D 401/06

140081

The present invention relates to a pharmaceutically acceptable salt of a imidazole compound which is mGluRS receptor antagonists and which is represented by the general formula I, a process for the manufacture thereof, as well as the manufacture of a composition for the treatment or prevention of mGluR5 receptor mediated disorders, such as acute and/or chronic neurological disorder,



wherein
R¹ signifies halogen or cyano;
R² signifies lower alkyl;

R³ signifies aryl or heteroaryl, which are optionally substituted by one, two or three substituents, selected from the group consisting of halogen, lower alkyl, cycloalkyl, lower alkyl-halogen, cyano, lower alkoxy, NR'R'' or by 1-morpholinyl, or by 1-pyrrolidinyl, optionally substituted by (CH₂)_{0,1}OR, or by piperidinyl, optionally substituted by (CH₂)_{0,1}OR, or by 1,1-dioxo-thiomorpholinyl or by piperazinyl, optionally substituted by lower alkyl or (CH₂)_{0,1}-cycloalkyl;

R is hydrogen, lower alkyl or (CH₂)_{0,1}-cycloalkyl;

R',R'' are independently from each other hydrogen, lower alkyl, (CH₂)_{0,1}-cycloalkyl or (CH₂)_nOR;

n is 1 or 2;

R⁴ is hydrogen, C(O)H, CH₂R⁵ wherein R⁵ is hydrogen, OH, C₁-C₆-alkyl, C₃-C₁₂-cycloalkyl.


152/2007 Syngenta
Participations AG.,
Switzerland
Syngenta Limited,
United Kingdom

“Novel insecticidally active heterobicyclic
anthranilamide compound”

CO7D 401/14, CO7D 409/14, CO7D 413/14,
CO7D 417/14, AO1N 43/00.

140082

Compound of formula I



wherein

G₁, G₂, G₃ and G₄ form together with the two carbon atoms to which G₁ and G₄ are attached, an aromatic ring system; wherein

G₁ is nitrogen, sulfur, oxygen, a direct bond or C-R_{5a};

G₂ is nitrogen, sulfur, oxygen, a direct bond or C-R_{5b};

G₃ is nitrogen, sulfur, oxygen, a direct bond or C-R_{5c};

G₄ is nitrogen, sulfur, oxygen, a direct bond or C-R_{5d}; with the provisos that

- a) at least one substituent G represents nitrogen, sulfur or oxygen,
- b) not more than 1 substituent G can at the same time form a direct bond,
- c) not more than 2 substituents G can be oxygen or sulfur, and
- d) 2 substituents G as oxygen and/or sulfur are separated by at least one carbon atom; each of Z₁, and Z₂, which may be the same or different, represents oxygen or sulfur; each of R₂, R₃, R₂₀, R_{1a}, R_{1b}, R_{5a}, R_{5b}, R_{5c}, and R_{5d} represents organic substituents; and D is optionally substituted phenyl or a 5-6-membered nitrogen containing heterocycle; can be used as insecticidal active ingredients and can be prepared in a manner known per se.

1542/2008 Mehjabeen,
Dr. Shakeel Ahmad,
Asad Raza,
Karachi,
Pakistan

“A process for preparation of novel herbal composition for treatment of fungal disease”

A61K 31/00

140083

A synergistic anti-fungal composition for use on skin, including: (a) an extract of seeds of *pisum sativum*, *vigna mungo*, *vigna unguiculata*, and *vigna radiata* (b) and cinnamon oil in an appropriate ratio of 80% by weight of extracts (20% of each extract) and 20% by weight of cinnamon oil. The composition of the present invention has been shown to have unexpectedly prolonged anti-fungal activity when applied on the skin in the form of lotion.

SEALING FEES DUE

Notice is hereby given that the Patent may now be sealed on the application referred to below if it is desired that Patent should be sealed a request on the prescribed Form-10 accompanied by the fee of Rs.2250/- should be sent to the Controller of Patents and Designs, The Patent Office, Karachi.

139822	Glaxo Wellcome Australia Limited, Australia	113/1998
139823	Eli Lilly and Company, USA	1230/1998
139824	Eli Lilly and Company, USA	682/2000
139825	Sanofi-Aventis Deutschland GmbH, Germany	244/2004
139826	Wyeth, USA	249/2004
139827	The Gillette Company, USA	211/2005
139828	Fosroc International Limited, Great Britain	361/2005
139829	Unilever PLC, United Kingdom	1356/2006
139830	GCG Holdings Limited, Baganas	41/2007

(MRS. YASMEEN ABBASI)
CONTROLLER OF PATENTS
Tel: 9215488